Takeda Pharmaceutical Co. Ltd. lists three research areas – GI, oncology and CNS – from which it wants to grow a more specialty-based business, but the Tokyo, Japan-based business also remains active in researching novel vaccines, including a potential dengue vaccine, TAK-003, for which it has just released an interim 18-month analysis of Phase II data that backed the start of the Phase III TIDES study in September 2016.
Takeda's Dengue Vaccine Still Promising, But Could Be A Niche Market
Long-term Phase II data have backed Takeda's drive to study its dengue vaccine in Phase III, but to grow the market the company may have to reverse the reluctance of countries to fund public vaccination campaigns.
